Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001214659-24-017295
Filing Date
2024-10-08
Accepted
2024-10-08 16:20:17
Documents
2
Group Members
CONCENTRA BIOSCIENCES, LLCKEVIN TANGTANG CAPITAL PARTNERS III, INCTANG CAPITAL PARTNERS IV, INCTANG CAPITAL PARTNERS, LP

Document Format Files

Seq Description Document Type Size
1 g107240sc13d.htm SC 13D 134094
2 GRAPHIC ktang_sig.jpg GRAPHIC 3358
  Complete submission text file 0001214659-24-017295.txt   140664
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
TANG CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001232621 (see all company filings)

EIN.: 461592449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90539 | Film No.: 241360539
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)